<DOC>
	<DOCNO>NCT00021749</DOCNO>
	<brief_summary>This non-randomized study test safety effectiveness Genasense patient CLL .</brief_summary>
	<brief_title>Phase I/II Study Genasense Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This study two-part phase I-II study . Part 1 determine MTD Genasense patient CLL . This dose tested non-randomized , multi-center , Phase II sequential clinical trial Genasense use alone treatment patient advance CLL . Pharmacokinetics Genasense kinetics Bcl-2 regulation re-expression CLL cell follow select patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Any age Must receive least one chemotherapy regimen include fludarabine Measurable disease At least 3 week since biological therapy radiation therapy chronic lymphocytic leukemia No previous stem cell transplantation At least 3 week since surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>CLL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Chronic</keyword>
	<keyword>Cancer</keyword>
	<keyword>Adult</keyword>
	<keyword>Lymphocytic</keyword>
	<keyword>Genasense</keyword>
	<keyword>G3139</keyword>
	<keyword>Genta</keyword>
	<keyword>Bcl-2</keyword>
	<keyword>Antisense</keyword>
	<keyword>Oligonucleotide</keyword>
	<keyword>oblimerson</keyword>
</DOC>